The Lancet thelancet.com

[Comment] Front-line durvalumab and BCG in the treatment of non-muscle-invasive bladder cancer

thelancet.com·30w

[Articles] Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of...

thelancet.com·30w

[Articles] Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasop...

thelancet.com·30w

[Comment] Treatment of MSSA bacteraemia: a call for a personalised approach

thelancet.com·30w

[Articles] Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi...

thelancet.com·30w

[Articles] Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial

thelancet.com·30w

[Comment] Perioperative camrelizumab plus rivoceranib versus surgery in resectable hepatocellular carcinoma

thelancet.com·30w

[Articles] Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial

thelancet.com·30w

[Articles] Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis

thelancet.com·30w

[Articles] Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label...

thelancet.com·30w

[Comment] The arrival of antibody drug conjugates in nasopharyngeal cancer

thelancet.com·30w

[Articles] Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi...

thelancet.com·30w

[Comment] The arrival of antibody drug conjugates in nasopharyngeal cancer

thelancet.com·30w

[Articles] Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasop...

thelancet.com·30w

[Articles] Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of...

thelancet.com·30w

[Comment] Perioperative camrelizumab plus rivoceranib versus surgery in resectable hepatocellular carcinoma

thelancet.com·30w

[Articles] Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-infe...

thelancet.com·31w

[Articles] Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis

thelancet.com·31w

[Comment] Treatment of MSSA bacteraemia: a call for a personalised approach

thelancet.com·31w

[World Report] In Timor-Leste, even modest cuts in US foreign aid add up

thelancet.com·31w

Log in to enable infinite scrolling